论文部分内容阅读
(2015-08-07)[2015-07-31]http://www.sda.gov.cn/WS01/CL0087/125700.html2015年7月2日,食品药品监管总局发布《关于公布银杏叶药品专项监督抽验初步结果的通告》(2015年第25号),公布了第一批抽验结果。现将第二批抽验结果通告如下:一、在抽验的194批药品中检出不合格药品118批,涉及31家药品生产企业(详见附件)。有29家企业102批药品为企业自检不合格,监督抽验结果与企业自检结果一致,相关企业已采取召回措施并公布了召回信息。二、共检出4家企业16批药品企业自检合格,监督抽验结果不合格。其中,新发现湖北午时药业股份有限公司自检结果与
(2015-08-07) [2015-07-31] http://www.sda.gov.cn/WS01/CL0087/125700.html On July 2, 2015, the Food and Drug Administration released the "Announcement on the Publication of Ginkgo Biloba Drugs Notice of Initial Results of Special Supervisory Sampling (No. 25 of 2015) released the first batch of test results. The second batch of test results is hereby announced as follows: First, 118 batches of substandard drugs were detected among the 194 batches tested, involving 31 pharmaceutical manufacturers (see attached). There are 29 batches of 102 batches of drugs for the enterprise self-test failed, the results of supervision and test self-test results consistent with the relevant enterprises have taken recall measures and announced the recall information. Second, a total of four batches of pharmaceutical companies were found to have passed the self-test of four batches of pharmaceutical companies and the result of supervision and sampling failed. Among them, the newly discovered Hubei afternoon Pharmaceutical Co., Ltd. self-test results and